Last reviewed 2026-04-20 · How we verify

Captodiam (CAPTODIAME)

Phase 2 active Small molecule

Captodiam (generic name: CAPTODIAME) is a captodiame drug. It is currently in Phase 2 development for Anxiety disorder.

Captodiam works by modulating the activity of certain neurotransmitters in the brain.

Captodiam, also known as CAPTODIAME, is a small molecule drug in the captodiame class. It is used to treat anxiety disorder. The commercial status of Captodiam is unclear, and it is not known if it is patented or available as a generic. Further information on its approval status, half-life, bioavailability, and generic manufacturers is not available. As a result, key safety considerations and pharmacological details are also unknown.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CAPTODIAME
Drug class	captodiame
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

In simple terms, Captodiam helps to calm the brain by influencing the levels of certain chemicals, such as serotonin and dopamine, which play a role in regulating emotions and mood.

Approved indications

Anxiety disorder

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Captodiam CI brief — competitive landscape report
Captodiam updates RSS · CI watch RSS

Frequently asked questions about Captodiam

What is Captodiam?

Captodiam (CAPTODIAME) is a captodiame drug, indicated for Anxiety disorder.

How does Captodiam work?

Captodiam works by modulating the activity of certain neurotransmitters in the brain.

What is Captodiam used for?

Captodiam is indicated for Anxiety disorder.

What is the generic name of Captodiam?

CAPTODIAME is the generic (nonproprietary) name of Captodiam.

What drug class is Captodiam in?

Captodiam belongs to the captodiame class. See all captodiame drugs at /class/captodiame.

What development phase is Captodiam in?

Captodiam is in Phase 2.

Drug class: All captodiame drugs
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Anxiety disorder

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing